Last Week Tonight in BioPharma: Week of June 8th, 2026
A major GSK acquisition, Tango puts PRMT5 back on the radar, a record-setting IPO, and much more!
Welcome back to Last Week Tonight in BioPharma (LWTB). What a week!
GSK dropped its biggest deal ever, paying $10.6 billion for Nuvalent. Tango therapeutics wows with new PDAC combo data. Lots of GLP-1 data presented at the ADA 2026 conference, but Lilly’s retatrutide sill reigns supereme. Parabilis shattered the biotech IPO record at $670 million, and Takeda’s zasocitinib crushed SOTYKTU in a direct head-to-head.
All that and more below. Let’s get into it!
📡 PRESS RELEASE DECODER
What the press releases actually mean
Tango’s Vopimetostat plus Daraxonrasib Hits 92% ORR in Heavily Pre-Treated MTAP-Deleted Pancreatic Cancer
📅 June 8, 2026 | 🏥 Tango Therapeutics (TNGX 0.00%↑), Revolution Medicines ( RVMD 0.00%↑) | 💊 Vopimetostat (MTA-cooperative PRMT5 inhibitor) plus daraxonrasib or zoldonrasib (RAS(ON) inhibitors)
Tango reported initial Phase 1/2 combination data for vopimetostat plus Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted RAS-mutant cancers. In the vopimetostat plus daraxonrasib arm, 12 evaluable second and third line PDAC patients delivered a 92 percent ORR (11 of 12, nine confirmed), 100 percent DCR, and a 90 percent six-month PFS rate with median PFS not reached. Three NSCLC patients in the same combination delivered 100 percent ORR. The vopimetostat plus zoldonrasib arm in 27 evaluable PDAC patients delivered 52 percent ORR, 96 percent DCR, and 74 percent six-month PFS. Both combinations were well tolerated with no Grade 4 or 5 related AEs and no AE-driven discontinuations. The population was heavily pre-treated with more than half in third line and 70 to 77 percent with liver metastases. Tango plans to advance vopimetostat plus daraxonrasib into Phase 3 in first-line MTAP-deleted PDAC.
🧠 BPS Take: Coming off of the stellar daraxonrasib data we saw at ASCO in 2L+ PDAC, this combo data from Tango continues to imbue promise for the future treatment paradigm in PDAC and reinvigorate interest in the synthetic lethality mechanisms. MTAP-deleted PDAC represents roughly 40% of the market. In these types of tumor, PRMT5 inhibition works by completely shutting down an already weakened, vital cellular regulator that is already being throttled by a buildup of metabolic waste (MTA), pushing the cancer cell over the edge into cell death while leaving healthy cells unharmed. Adding KRAS inhibition onto that cuts off the tumors primary growth engine, leading to the synergistic uptick in ORR.
This is a small samples size (n=12) and short follow-up, but its rare to get this high of an ORR and have it not mean anything, especially when you consider SoC in these patients was generating single-digit ORRs. Credit to the Tango team too for planning ahead and doing a combo study with daraxonrasib, even before it became standard of care in PDAC. That shows quality product planning, anticipating the changing SoC.
You can imagine Tango is now on the BD radar for many companies with these data. BMS has their own PRMT5 inh in P2/3 and there are a slew of at least a couple dozen other PRMT5 inhibitor in active clinical development across the US, EU, and China. Notably Amgen and GSK previously discontinued their own PRMT5 programs. One name to track in this space is Ideaya ( IDYA 0.00%↑ ), which is developing IDE892 (PRMT5 inh) and is also targeting PDAC in combination with Roche’s pan-RAS inhibitor (RG6505).
Takeda’s $4B TYK2 Bet Pays Off: Zasocitinib Clears Skin at 2.5x the Rate of SOTYKTU in Head-to-Head Phase 3
📅 June 11 | 🏢 Takeda ( TAK 0.00%↑ ) | 💊 zasocitinib | 🏷 Phase 3 Head-to-Head Data
Takeda ( TAK 0.00%↑ ) announced Phase 3 results showing zasocitinib achieved 35% PASI 100 (complete skin clearance) compared to approximately 14% for SOTYKTU (deucravacitinib, Bristol Myers Squibb, $BMY) in a direct head-to-head trial in patients with moderate-to-severe plaque psoriasis. The 2.5x superiority on complete skin clearance was statistically significant. This follows a prior head-to-head study in which zasocitinib also outperformed Amgen’s ($AMGN) OTEZLA (apremilast).
Takeda acquired zasocitinib from Nimbus Therapeutics for $4 billion upfront in 2022, at a time when zasocitinib had no approved indication and the deal was widely viewed as expensive for an early-stage asset. SOTYKTU, the first-approved TYK2 inhibitor, generated $291 million in 2025 revenue. BMS has separately signaled it plans to reduce promotional investment in SOTYKTU in dermatology in a number of markets. The next major readout for zasocitinib is in inflammatory bowel disease, covering ulcerative colitis and Crohn’s disease, expected later in 2026.
🧠 BPS Take: Takeda paid $4 billion upfront for zasocitinib, an “AI-designed” drug, when the asset had no approval and the TYK2 proof of concept was still being established. Many called that an expensive bet back in 2022. A 2.5x head-to-head win on complete skin clearance over an approved in-class competitor makes it look like an underpay in retrospect.
The next major readouts are in IBD, with P2b data in Crohn’s and Ulcerative Colitis, two massive markets, upcoming by the end of this year. AbbVie’s RINVOQ (upadacitinib) and J&J’s biologic agents dominate that space, with RINVOQ alone doing over $5 billion annually across indications. If TYK2 inhibition works in IBD with clinical superiority data, this franchise becomes a genuine multi-billion dollar bet. SOTYKTU itself failed in IBD and a win there would further validated the precision-targeting of TYK2 via an AI-optimized drug design. The IBD data is the moment this story either gets much bigger or stays a dermatology niche win.
Furthermore, this could be the first actual win for AI-designed drugs, which to this point have largely been unimpressive in clinical studies. SOTYKTU came first, but Nimbus and Schrodinger used their advanced computing tools to look at SOTYKTU and figure out how to optimize it — that to me is where AI for drug development is really able to showcase its value today. Once you know the target and have some prior attempts at hitting that target, use that data to figure out how we can really hit that target much more cleanly.
ADA 2026 Bundle: Pfizer, Roche, and Novo Show They Are All Competing for the Same Patients Against Lilly
📅 June 8-11 | 🏢 CMS/HHS + Eli Lilly ( LLY 0.00%↑ ) + Pfizer ( PFE 0.00%↑ ) + Roche ( $RHHBY ) + Zealand Pharma ( $ZEAL ) + Novo Nordisk ( NVO 0.00%↑ ) | 💊 WEGOVY / ZEPBOUND / FOUNDAYO / retatrutide / berobenatide / enicepatide / CagriSema |
At ADA 2026, Lilly presented extended Phase 3 data from TRIUMPH-1 for retatrutide: 28.3% mean weight loss at 80 weeks (70.3 lbs), with 45.3% of patients achieving 30% or greater weight loss and 65.3% reaching a BMI below 30. Pfizer’s berobenatide showed approximately 16% weight loss by 60 weeks in the Phase 2b VESPER trial. Roche-Zealand’s enicepatide (CT-388), a dual GLP-1/amylin agonist, showed 18-22.5% placebo-adjusted weight loss at the highest dose tested. Novo Nordisk’s CagriSema showed approximately 14.2% weight loss in the REIMAGINE T2D trial in patients with type 2 diabetes.
🧠 BPS Take: Pfizer at 16% and Roche-Zealand at 18-22% are real numbers, but they are not threatening Lilly’s ceiling. Retatrutide at 28% with nearly half of patients losing 30% or more is a different category of efficacy. Novo’s CagriSema at 14% in a T2D population is trailing across all mechanisms. The market will expand fast enough that multiple players can build profitable franchises here, but it will be important for each to find its niche population as treatment moves towards a more precision-medicine type approach. Future pricing considerations will also be a major driver here, as many employer plans are looking drop coverage of GLP-1 drugs in 2027 because they are getting too expensive, making the more price-transparent cash-pay direct-to-consumer market even more critical for driving commercial success.
🌐 CONNECTING THE DOTS
When the outside world meets biopharma
Not much I wanted to highlight in this section this week, so I’ll take this time to plug my paid tier 😅.
If you subscribe to Big Pharma Sharma (BPS) for LWTB and you like what you read, consider upgrading to paid to read my best work.
I recently did a deep dive into two interesting data readouts from ASCO 2026 in Lung Cancer. I compared Summit’s ivonescimab to Merck/Kelun’s Sac-TMT and gave you my take on who looks to be the better drug thus far.
You can check that out by following the link below
💰 FOLLOW THE MONEY
Deals, dollars, and what they signal
IPO Bundle: Parabilis Sets a New Biotech IPO Record at $670M While Kardigan Lines Up Cardiovascular. The Window Is Fully Open
📅 June 10 to 11, 2026 | 🏥 Parabilis Medicines ( PBLS 0.00%↑ ), Kardigan ( $KARD ), Regeneron ( REGN 0.00%↑ ) | 💊 Zolucatetide (Helicon peptide targeting beta-catenin), Kardigan cardiovascular pipeline (danicamtiv, ataciguat, tonlamarsen) | 📄 IPO Pricing and Terms Set
Parabilis priced its upsized IPO on June 10 at $20 per share, selling 33.5M shares for $670M in gross IPO proceeds. The stock opened at $33.35 on its first trading day, a 67 percent gain over the IPO price. Parabilis trades on Nasdaq under the ticker PBLS. The company is the rebranded FogPharma, founded by Gregory Verdine of Harvard and led by Mathai Mammen, the former CSO of Johnson & Johnson (JNJ). The $670M raise is the largest VC-backed biotech IPO on record, eclipsing Kailera Therapeutics ($625M, May 2026) and Moderna’s 2018 IPO ($604M). Concurrent with the offering, Regeneron (REGN) closed on a $75M private placement at $18 per share, bringing total proceeds to roughly $745M. The $75M equity check was the execution of Regeneron’s previously committed equity tranche from the May 18 collaboration, which included $50M upfront plus a $75M equity commitment under the broader $2.3B antibody-Helicon conjugate deal. Lead asset zolucatetide is a beta-catenin Helicon peptide targeting desmoid tumors with Phase 3 enrollment planned for H1 2027.
Kardigan set IPO terms on June 11 to raise up to $373M by offering 23.3M shares at a $14 to $16 range, targeting a $1.4B valuation. The pipeline covers danicamtiv (cardiac myosin activator for genetic dilated cardiomyopathy, Phase 2b/3), ataciguat (sGC activator for calcific aortic valve stenosis, Phase 2b), and tonlamarsen (antisense oligonucleotide targeting hepatic angiotensinogen for treatment-resistant hypertension, licensed from Ionis). The 2026 biotech IPO market has now produced more than a dozen offerings, with median raises above $300M, roughly 2x the 2025 median.
🧠 BPS Take: A $670M raise with an upsize and a 67 percent first-day pop tells you the institutional book was massively oversubscribed at the IPO price, which means bankers left money on the table and the buy-side was hungry.
Underneath all that is a thematic note of interest that could carry-through to more large rounds in the future: drugging the undruggable. That concept is having a moment, buttressed by the daraxonrasib PDAC data, showing that KRAS, which was once thought to not be druggable, is in fact a druggable target. The Helicon peptide platform appears to be a credible attempt at drugging undruggable intracellular targets like beta-catenin. Pair that with a late-stage asset entering pivotal studies and a relatively short line of sight into a commercial program, and you have yourselves a massive fundraising event in Oncology. Other companies who can credibly show movement on once untouchable targets with clinical data to back it up (whether it be with the help of AI, a novel platform, or some other means) will likely also see a big pot of gold coins for them at the end of the rainbow.
It will be interesting to see how Kardigan fairs when the final numbers come in for its IPO. My guess is they will do well too, given that they have multiple late-stage assets, both balancing risk and optimizing upside, plus a team that “has done it before” with the MyoKardia connection. The consistent theme across most of the large IPOs we have seen throughout this year has been the existence of validated mid-to-late-stage data. I don’t see that changing anytime soon. IPO markets are open if you have the clinical data to back it up.
GSK’s Biggest Deal Ever: $10.6 Billion for Nuvalent Bets the House on Next-Gen Lung Cancer
📅 June 9 | 🏢 GSK ( GSK 0.00%↑ ) + Nuvalent ( NUVL 0.00%↑ ) | 💊 zidesamtinib (NVL-520) + neladalkib (NVL-655) | 🏷 M&A Acquisition
GSK announced an agreement to acquire Nuvalent for $10.6 billion, or $124 per share in cash, representing a 40% premium to Nuvalent’s last closing price and a 26% premium to its 30-day volume-weighted average price. The deal is expected to close in Q3 2026, subject to regulatory approval. This is GSK’s largest acquisition in its corporate history.
Nuvalent’s lead assets are two next-generation kinase inhibitors for non-small cell lung cancer. Zidesamtinib (NVL-520) targets ROS1-positive NSCLC and has a PDUFA date of September 18, 2026. Neladalkib (NVL-655) targets ALK-positive NSCLC and has a PDUFA date of November 27, 2026. Both drugs were specifically designed to overcome acquired resistance to current standard-of-care agents, including Pfizer’s lorlatinib and earlier-generation crizotinib. The pipeline also includes NVL-330, a Phase 1 HER2 inhibitor for NSCLC.
🧠 BPS Take: GSK is paying a 40% premium for two drugs that both have FDA decisions within six months of close, giving them two immediate new inline commercial assets to market in two very competitive spaces. The success or failure of this deal will hinge on the commercial performance of Nuvalent’s ALK and ROS inhibitors. The resonance of the differentiation story, being able to be a more mutation-resistant way of targeting these well-validated driver mutations, adding CNS penetrance to the equations to target brain mets, and with improved tolerability compared to existing options as a third/fourth-to-market offering will have to carry the day. Expansion into earlier lines of therapy will be key as well to expand the total addressable markets of these two drugs. On the surface, $11B for these set of drugs feels like a lot, but we should wait to judge until we see the commercial traction.
On a different level, this tells you that there is Big Pharma interested in better versions of validated targets (so called “me-betters”) if the data package is robust enough.
On a separate note, new GSK CEO, Luke Miels, has been an active acquirer since taking over the helm of the company. This Nuvalent deal is his largest yet, and pairs nicely with GSK’s B7-H3 ADC asset in Lung cancer. This deal also continues GSK’s slow re-entry back into Oncology, after largely exiting the space back in 2015. The company now has some niche commercial assets in JEMPERLI, BLENREP, OJJAARA, and ZEJULA but has clearly eyed Lung Cancer as its next frontier.
Roche Pays Nurix $700M Upfront, Up to $2.3B Total for Bexobrutideg
📅 June 8, 2026 | 🏥 Roche (RHHBY) and Nurix Therapeutics (NRIX) | 💊 Bexobrutideg (NX-5948), brain-penetrant oral BTK degrader | 📄 Exclusive Licensing and Co-Development/Co-Commercialization Agreement
Roche licensed bexobrutideg from Nurix for $700M upfront with up to $2.3B in total deal value across development, regulatory, and sales milestones. Development costs split 60 percent Roche and 40 percent Nurix. US commercialization is co-commercialized with profits and losses split 50/50. Outside the US, Roche commercializes with Nurix receiving low to high teens royalties. The asset is an orally bioavailable, brain-penetrant BTK degrader (not inhibitor) that eliminates both kinase and scaffolding functions of BTK, with the mechanistic claim that it overcomes resistance mutations that defeat current BTK inhibitors. Phase 3 initiation is planned for summer 2026 in second-line CLL. The deal scope spans B-cell malignancies, chronic spontaneous urticaria in immunology, and multiple sclerosis in neurology. Roche cited NHL plus CLL market projections of $41B by 2031 with BTK class at approximately $19B.
🧠 BPS Take: The deal terms here are fairly standard and this feels like a strong way for Nurix to monetize its key lead asset with an established commercial player. Multiple Sclerosis and CLL are two spaces Roche knows well and this deal speaks to me as a maneuver guided at fortifying the long-term stability of the company’s commercial prospects in those two diseases.
Still there is inherent risk with this mechanism of action in both of the major areas Roche is looking to achieve commercial success in. CLL is really damn competitive. You still have a multitude of on-market BTK inhibitors to contend with that are rather well-tolerated and used chronically. Roche and Nurix will need to make the case to switch to a degrader as the move into earlier lines of therapy, touting the longer-term BTK suppression that may be immune to resistance mutations, while also competing with degraders from other players like Lilly and BeOne.
On the MS front, BTK data to date has been rather mixed. German Merck’s evobrutinib, completes whiffed in its MS studies. Sanofi’s tolebrutinib also had mixed data that resulted in an FDA rejection. However, Roche’s own BTK inhibitor, fenebrutinib, has proved to be successful here, and will enter the market as a potential class-leader. The addition of bexobrutideg feels like Roche repeating its strategy with RITUXAN, GAZYVA, and OCREVUS — using RITUXAN as an anchor CD20 mAb and building towards next-generation versions in GAZYVA and OCREVUS. While OCREVUS turned out to be a commercial success story in MS, GAZYVA never really gained much traction in CLL, somewhat suffering from the high bar RITUXAN had already set. How Roche manages their two BTK offerings now in the wake of their experience with the CD20 programs it once juggled will be key to monitor.
Back next week with more BioPharma strategy takes! Share this with a friend or colleague if you found it helpful.